Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arctic Bioscience AS (ABS.OL)
Ørsta, NO
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.45% | +0.30% | +0.00% | +0.00% | -10.33% | -9.84% | -2.94% | -62.92% | -85.58% | -88.00% | -88.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-7.8% Q4'25: +55.8% (vs Q4'23)
-
EPS growth Medical - Pharmaceuticals: +20.2%+19.2% Q4'25: +16.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-82.5% Q4'25: -35.2% (vs Q4'23)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-89.7% Q4'25: -75.5% (vs Q4'23)
-
ROIC Medical - Pharmaceuticals: +6.1%-15.3% Q4'25: -29.5% (vs Q4'23)
-
Share dilution Medical - Pharmaceuticals: +0.0%+6.0% Q4'25: +6.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-1.73× Q4'25: -0.90× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
21.52M
est: 28.50M (-24.5%)
|
34.27M
est: 45.00M (-23.8%)
|
33.76M
est: 31.88M (+5.9%)
|
43.48M
est: 57.00M (-23.7%)
|
40.10M
est: 79.00M (-49.2%)
|
58.00M
58.00M – 58.00M
-26.6% YoY
|
| EBITDA |
-37.94M
est: -27.33M (-38.8%)
|
-30.29M
est: -43.15M (+29.8%)
|
-43.20M
est: -29.92M (-44.4%)
|
-39.63M
est: -53.49M (+25.9%)
|
-35.97M
est: -74.14M (+51.5%)
|
-54.43M
-54.43M – -54.43M
+26.6% YoY
|
| EBIT |
-40.46M
est: -28.46M (-42.2%)
|
-34.02M
est: -44.93M (+24.3%)
|
-48.59M
est: -31.18M (-55.8%)
|
-44.78M
est: -55.74M (+19.7%)
|
-35.97M
est: -77.26M (+53.4%)
|
-56.72M
-56.72M – -56.72M
+26.6% YoY
|
| Net Income |
-42.58M
est: -36.51M (-16.6%)
|
-34.02M
est: -37.14M (+8.4%)
|
-45.51M
est: -51.50M (+11.6%)
|
-47.93M
est: -32.35M (-48.2%)
|
-41.03M
est: -53.64M (+23.5%)
|
-23.99M
-23.99M – -23.99M
+55.3% YoY
|
| SGA |
—
est: 7.37M (-100.0%)
|
—
est: 11.64M (-100.0%)
|
23.51M
est: 8.25M (+185.1%)
|
25.95M
est: 14.74M (+76.0%)
|
—
est: 20.43M (-100.0%)
|
15.00M
15.00M – 15.00M
-26.6% YoY
|
| EPS |
-1.75
est: -1.44 (-21.9%)
|
-1.40
est: -1.46 (+4.1%)
|
-1.79
est: -1.91 (+6.3%)
|
-1.88
est: -1.20 (-56.7%)
|
-1.52
est: -1.99 (+23.6%)
|
-0.89
-0.89 – -0.89
+55.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christer L. Valderhaug | Chief Executive Officer | — | male |
| Daniele Mancinelli | Chief Technical Officer | — | male |
| Hogne Hallaraker | Founder & Chief Scientific Officer | — | male |
| Jone R. Slinning | Chief Financial Officer | — | male |
| Kim Frode Thorup | EVP of B2B Nutra | — | male |
| Para Ghildyal-Palani | Regulatory Manager | — | — |
| Per Christian Sæbo | Chief Operating Officer | — | male |
| Runhild Gammelsaeter | Global Medical Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ABS.OL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
